Home > Insider Trading > Filing (0000929638-24-001743)

Filing Details

Accession Number:: 0000929638-24-001743
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-05-08 16:23:14
Reporting Period:: 2024-05-06

Accepted Time:: 2024-05-08 16:23:14
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1314102	Eyepoint Pharmaceuticals Inc.	EYPT	Laboratory Analytical Instruments (3826)	262774444

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1583977	Cormorant Asset Management, Lp	200 Clarendon Street 52Nd Floor Boston MA 02116	No	No	No	No
1599214	Bihua Chen	C/O Cormorant Asset Management, Lp 200 Clarendon Street, 52Nd Floor Boston MA 02116	No	No	No	No
1618442	Cormorant Global Healthcare Master Fund, Lp	200 Clarendon Street 52Nd Floor Boston MA 02116	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-05-06	642,847	$11.70	8,117,847	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2024-05-06	207,153	$12.36	8,325,000	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Footnotes

Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Represents the weighted average sale price of Common Stock (the "shares") purchased in a series of open market transactions on the transaction date at prices ranging from $11.08 to $12.07 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission (the "SEC"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.
Represents the weighted average sale right of the shares purchased in a series of open market transactions on the transaction date at prices ranging from $12.08 to $12.95 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.